|
End-of-day quote
2026-09-30
|
5-day change
|
1st Jan Change
|
|
63.17 CNY
|
-1.33%
|
 |
-6.08%
|
+5.87%
|
|
09-28 |
Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.
|
CI
| |
09-20 |
Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index
|
CI
| |
08-25 |
Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million.
|
CI
| |
08-25 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026
|
CI
| |
04-28 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
04-23 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
|
CI
| |
04-22 |
Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.
|
CI
| |
04-22 |
Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.
|
CI
| |
04-22 |
Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.
|
CI
| |
02-26 |
Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.
|
CI
| |
02-24 |
Trading in Tibet Duo Rui Pharmaceutical's shares to halt
|
RE
| |
01-20 |
Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.
|
CI
| |
12-04 |
Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.
|
CI
| |
25-10-23 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
25-10-12 |
Wang Qingtai, Cui Zihao and Cao Xiaobing signed an share transfer agreement to acquire 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 760 million.
|
CI
| |
25-09-29 |
Duorui Pharma Expects Control Change Amid Parents' Plan
|
MT
| |
25-09-28 |
Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2025.
|
CI
| |
25-09-28 |
Trading in Tibet Duo Rui Pharmaceutical's shares to halt
|
RE
| |
25-08-26 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25-04-24 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
25-04-17 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
|
CI
| |
24-11-03 |
Hubei Qingsong Yueyue Pharmaceutical Co., Ltd. agreed to acquire 5.66% stake in Hubei Tianji Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 68.8 million.
|
CI
| |
24-10-24 |
Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
|
CI
| |
24-10-10 |
Duorui Pharmaceutical to Acquire 70% Stake in Frontier Jianling Biotechnology for 271 Million Yuan
|
MT
| |
24-09-28 |
Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2024.
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
